or Try an Advanced Search...

    Technical Analysis for CANF - Can-Fite Biopharma Ltd Sponsored ADR (Israel)

    Grade Last Price % Change Price Change
    F 1.96 -1.51% -0.03
    CANF closed down 1.51 percent on Friday, November 15, 2024, on 58 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    Earnings due: Nov 28
    *** please verify all earnings dates ***
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical CANF trend table...
    Date Alert Name Type % Chg
    Wide Bands Range Expansion 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Down 4 Days in a Row Weakness 0.00%
    Down 5 Days in a Row Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Wide Bands Range Expansion -1.51%
    Down 3 Days in a Row Weakness -1.51%
    Down 4 Days in a Row Weakness -1.51%
    Oversold Stochastic Weakness -1.51%
    Wide Bands Range Expansion -5.31%
    Older End-of-Day Signals for CANF ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 1 day ago
    Possible Inside Day 1 day ago
    Up 3% 1 day ago
    Up 2% 1 day ago
    Up 1% 1 day ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    CANF Chart by TradingView
    Basic chart:

    Profile

    Can-Fite BioPharma, Ltd., a biotechnology company, develops drugs for the treatment of cancer and autoimmune inflammatory diseases. The company principally develops CF101 that is in Phase III study for the treatment of psoriasis; and has completed Phase II study for the treatment of rheumatoid arthritis and glaucoma, as well as completed Phase III study for the treatment of dry eye and Phase I study for the treatment of uveitis. It also develops CF102, which is in Phase II study for the treatment of hepatocellular carcinoma; and CF602 that has completed pre-clinical trial for the treatment of inflammatory diseases. The company was founded in 2000 and is based in Petach Tikva, Israel.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Cancer Immunology Treatment Of Cancer Inflammatory Diseases Psoriasis Rheumatoid Arthritis Glaucoma Carcinoma Arthritis Hepatocellular Carcinoma Uveitis Immunosuppressants Biotie Therapies Treatment Of Psoriasis Treatment Of Inflammatory Disease Treatment Of Inflammatory Diseases

    Is CANF a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 11 Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial
    Nov 5 Can-Fite BioPharma Secures Australian Patent for Obesity Drug
    Nov 4 Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia
    Oct 18 Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson
    Oct 9 Can-Fite stock rallies 17% on FDA orphan drug designation
    Oct 9 FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic Cancer
    Oct 7 Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on October 29
    Sep 24 Can-Fite gains after agreement for animal arthritis drug
    Sep 24 Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis
    Sep 16 Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health
    See more CANF news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 4.69
    52 Week Low 1.83
    Average Volume 105,438
    200-Day Moving Average 2.41
    50-Day Moving Average 2.25
    20-Day Moving Average 2.28
    10-Day Moving Average 2.09
    Average True Range 0.21
    RSI (14) 33.77
    ADX 17.05
    +DI 16.85
    -DI 17.06
    Chandelier Exit (Long, 3 ATRs) 2.48
    Chandelier Exit (Short, 3 ATRs) 2.57
    Upper Bollinger Bands 2.82
    Lower Bollinger Band 1.75
    Percent B (%b) 0.2
    BandWidth 46.81
    MACD Line -0.10
    MACD Signal Line -0.06
    MACD Histogram -0.0365
    Fundamentals Value
    Market Cap 11.85 Million
    Num Shares 6.05 Million
    EPS -1.48
    Price-to-Earnings (P/E) Ratio -1.32
    Price-to-Sales 17.07
    Price-to-Book 2.38
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.19
    Resistance 3 (R3) 2.20 2.14 2.15
    Resistance 2 (R2) 2.14 2.08 2.13 2.14
    Resistance 1 (R1) 2.05 2.05 2.02 2.04 2.12
    Pivot Point 1.99 1.99 1.98 1.98 1.99
    Support 1 (S1) 1.90 1.93 1.87 1.88 1.80
    Support 2 (S2) 1.84 1.90 1.83 1.78
    Support 3 (S3) 1.75 1.84 1.77
    Support 4 (S4) 1.73